GeoVax Labs (GOVX) to Release Earnings on Thursday

GeoVax Labs (NASDAQ:GOVX) is anticipated to release its earnings data before the market opens on Thursday, March 6th. Analysts expect GeoVax Labs to post earnings of ($0.79) per share and revenue of $2.38 million for the quarter.

GeoVax Labs Stock Up 4.9 %

Shares of NASDAQ:GOVX opened at $1.51 on Tuesday. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18. The business’s 50 day moving average price is $1.98 and its 200-day moving average price is $2.63.

Analysts Set New Price Targets

A number of research firms have commented on GOVX. Alliance Global Partners began coverage on GeoVax Labs in a research report on Monday, November 11th. They issued a “buy” rating and a $15.00 target price on the stock. D. Boral Capital restated a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a research report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a research report on Friday, November 15th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, GeoVax Labs has an average rating of “Buy” and a consensus price target of $14.20.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.